Geneva Capital Management LLC Lowers Position in Azenta, Inc. (NASDAQ:AZTA)

Geneva Capital Management LLC reduced its stake in Azenta, Inc. (NASDAQ:AZTA) by 1.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 481,862 shares of the company’s stock after selling 6,780 shares during the quarter. Geneva Capital Management LLC’s holdings in Azenta were worth $16,692,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of AZTA. Farther Finance Advisors LLC raised its position in Azenta by 788.1% in the 1st quarter. Farther Finance Advisors LLC now owns 968 shares of the company’s stock valued at $33,000 after buying an additional 859 shares during the last quarter. Headlands Technologies LLC purchased a new stake in Azenta in the 4th quarter valued at $40,000. Covestor Ltd raised its position in Azenta by 64.2% in the 4th quarter. Covestor Ltd now owns 2,043 shares of the company’s stock valued at $102,000 after buying an additional 799 shares during the last quarter. Quarry LP purchased a new stake in Azenta in the 4th quarter valued at $110,000. Finally, Sterling Capital Management LLC raised its position in Azenta by 39.8% in the 4th quarter. Sterling Capital Management LLC now owns 2,856 shares of the company’s stock valued at $143,000 after buying an additional 813 shares during the last quarter. 99.08% of the stock is owned by hedge funds and other institutional investors.

Azenta Price Performance

Shares of Azenta stock opened at $32.34 on Monday. The firm has a market cap of $1.48 billion, a PE ratio of -23.27 and a beta of 1.59. Azenta, Inc. has a 1 year low of $23.91 and a 1 year high of $60.60. The stock has a fifty day moving average price of $30.92 and a 200-day moving average price of $35.05.

Azenta (NASDAQ:AZTA) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.04). Azenta had a positive return on equity of 1.30% and a negative net margin of 10.31%. The business’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.06 EPS. As a group, equities analysts anticipate that Azenta, Inc. will post 0.53 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

AZTA has been the subject of several research analyst reports. Needham & Company LLC decreased their target price on Azenta from $59.00 to $40.00 and set a “buy” rating for the company in a research report on Wednesday, May 7th. Stephens initiated coverage on Azenta in a research report on Tuesday, July 22nd. They set an “equal weight” rating and a $35.00 target price for the company. Finally, Evercore ISI raised their target price on Azenta from $29.00 to $35.00 and gave the company an “in-line” rating in a research report on Tuesday, July 8th.

Azenta Company Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.